Let's look for copper and all cause mortality. I found five studies.
https://www.ncbi.nlm...pubmed/16570028
1. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality.
High copper values (4th quartile) were associated with a 50% increase in RRs for all-cause deaths (RR = 1.5; 95% confidence interval = 1.1-2.1), a 40% increase for cancer mortality (1.4; 0.9-2.2), and a 30% increase for cardiovascular mortality (1.3; 0.6-2.8) compared with low values (1st quartile). High magnesium values were negatively related to mortality with a 40% decrease in RR for all-cause (0.6; 0.4-0.8) and cardiovascular deaths (0.6; 0.2-1.2) and by 50% for cancer deaths (0.5; 0.3-0.8). Additionally, subjects with a combination of low zinc and high copper values had synergistically increased all-cause (2.6; 1.4-5.0) and cancer (2.7; 1.0-7.3) mortality risks. Similarly, combined low zinc and high magnesium values were associated with decreased all-cause (0.2; 0.1-0.5) and cancer (0.2; 0.1-0.8) mortality risks.
http://jamanetwork.c...article/1105975
2. Dietary Supplements and Mortality Rate in Older Women: The Iowa Women's Health Study
Results In multivariable adjusted proportional hazards regression models, the use of multivitamins (hazard ratio, 1.06; 95% CI, 1.02-1.10; absolute risk increase, 2.4%), vitamin B6 (1.10; 1.01-1.21; 4.1%), folic acid (1.15; 1.00-1.32; 5.9%), iron (1.10; 1.03-1.17; 3.9%), magnesium (1.08; 1.01-1.15; 3.6%), zinc (1.08; 1.01-1.15; 3.0%), and copper (1.45; 1.20-1.75; 18.0%) were associated with increased risk of total mortality when compared with corresponding nonuse. Use of calcium was inversely related (hazard ratio, 0.91; 95% confidence interval, 0.88-0.94; absolute risk reduction, 3.8%). Findings for iron and calcium were replicated in separate, shorter-term analyses (10-year, 6-year, and 4-year follow-up), each with approximately 15% of the original participants having died, starting in 1986, 1997, and 2004.
http://link.springer...0522-009-9251-1
3. Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population
Cu/Zn ratio may be considered an important clinical inflammatory-nutritional biomarker as well as a significant predictor of all-cause mortality in over 70-year-olds.
http://digitalcommon...chcres_articles
4. High Serum Cu and Cu/Zn Ratios Correlate with Impairments in Bone Density, Physical Performance and Overall Health in a Population of Elderly Men With Frailty Characteristics
In the present study we found significant relationships between high Cu/Zn ratios with lower
BMD, lean mass, strength and power, lower extremity function, cholesterol, hematocrit, and
ADLs. The measures represent clinically relevant indicators of health and independence in a
cohort of frail elderly men. Several recent studies demonstrated a clear link between
increased serum Cu levels and/or Cu/Zn ratios with several progressive, degenerative
diseases (Arnal et al. 2010; Viktorinova et al. 2009) and increased risk for all-cause
mortality in the elderly (Leone et al. 2006; Malavolta et al. 2010). Consistent with previous
reports, we found more consistent and robust associations with serum Cu/Zn ratios than with
Cu levels alone. Our results support use of the Cu/Zn ratio as a functional and predictive
biomarker for overall health, independence and frailty (Malavolta et al. 2010).
The importance of Cu in bone health has been studied in the context of Cu deficiency and
osteoporosis (Palacios 2006; Chaudhri et al. 2009; Lowe et al. 2002). Chaudhri et al.
(Chaudhri et al. 2009) found a linear relationship between serum Cu values and bone density
NIH-PA Author Manuscript in post-menopausal women. By contrast, the men in our study with low serum Cu levels had
BMD similar to those of the reference group. Those with high serum Cu and a high Cu/Zn
ratio had lower BMDs, possibly due to elevated PTH and low 25OHD. These conflicting
results may reflect sex differences in age-associated bone loss or may be due to our
evaluation of an older, more frail population. Nielsen et al. recently found that
supplementing postmenopausal women with Cu and Zn resulted in loss of BMD in those
consuming adequate dietary Zn, while Zn supplementation to reach 8 mg/d prevented BMD
loss. Serum Cu and Zn levels were not reported, precluding comparison to our Cu/Zn ratios.
Nevertheless, these results support our findings indicating that high Cu is negatively
associated with BMD.
There is a complex interplay of Cu and Zn with Mg (Nielsen et al. 2011; Nielsen et al.
2003). While Mg intake in our study group was below the RDA [320 mg/d; (Food and
Nutrition Board and Institute of Medicine 1997)], serum Mg levels were not assessed. Mg
deficiency is associated with decreased osteoblast function and increased osteoclast numbers
(Rude et al. 2009), increased all-cause mortality (Leone et al. 2006) and increased
inflammatory markers (Chacko et al. 2010; Chang et al. 2012). Future studies aimed at
assessing interplay between Cu, Zn and Mg should be informative.
The serum Cu/Zn ratio has been studied in the context of several chronic progressive
diseases. High ratios predicted mortality in cardiovascular and cancer patients in several
prospective studies with 3.5 to 18 year follow-ups (Leone et al. 2006; Malavolta et al. 2010;
Reunanen et al. 1996). Our measures of serum Cu and Zn by mass spectrometry were
consistent with previous values using similar methods (Easter et al. 2010; Malavolta et al.
2010). We found similarly impaired physical function in those in the highest Cu/Zn ratio
group. Older men in the high serum Cu group demonstrated deficits in walking speed and
Get-Up-and-Go test, tasks with a strong cardiovascular component. In contrast, men in the
high serum Cu/Zn ratio group displayed more impaired muscle strength and mass. This
curious divergence likely speaks to distinct interactions between the roles of Cu and Zn in
the cardiovascular and musculoskeletal systems. In a cross-sectional study, Mezzeti et al.
(Mezzetti et al. 1998) found an association between high serum Cu and LDL and
triglycerides that purportedly contributed to the association with cardiovascular disease. We
found that a high Cu/Zn ratio predicted lower triglyceride and total cholesterol levels. These
conflicting results may reflect a survivor effect in the frail elderly and/or differences in
participant selection criteria between studies.
http://www.tandfonli...762.2014.901510
5. Copper, ceruloplasmin, and long-term cardiovascular and total mortality (The Ludwigshafen Risk and Cardiovascular Health Study)
Background. Copper and its main transport protein ceruloplasmin have been suggested to promote the development of atherosclerosis. Most of the data come from experimental and animal model studies. Copper and mortality have not been simultaneously evaluated in patients undergoing coronary angiography. Methods and results. We examined whether serum copper and ceruloplasmin concentrations are associated with angiographic coronary artery disease (CAD) and mortality from all causes and cardiovascular causes in 3253 participants of the Ludwigshafen Risk and Cardiovascular Health Study. Age and sex-adjusted hazard ratios (HR) for death from any cause were 2.23 (95% CI, 1.85–2.68) for copper and 2.63 (95% CI, 2.17–3.20) for ceruloplasmin when we compared the highest with the lowest quartiles. Corresponding hazard ratios (HR) for death from cardiovascular causes were 2.58 (95% CI, 2.05–3.25) and 3.02 (95% CI, 2.36–3.86), respectively. Further adjustments for various risk factors and clinical variables considerably attenuated these associations, which, however, were still statistically significant and the results remained consistent across subgroups. Conclusions. The elevated concentrations of both copper and ceruloplasmin are independently associated with increased risk of mortality from all causes and from cardiovascular causes.
Copper seems to consistently be shit!! I didnt cherry pick or anything. I look for copper and it's aaaall bad. I look for magnesium and its all good.
Edited by Skyguy2005, 08 May 2017 - 07:19 PM.